| dc.creator |
Sudhakar Pemminati, Gopalakrishna HN, Ashok Varma K, Maitrayee Chakraborty, Bheemesh V, Chetan G, Anupama Hegde, Ashok K Shenoy |
|
| dc.date |
2011 |
|
| dc.date.accessioned |
2013-05-30T13:15:08Z |
|
| dc.date.available |
2013-05-30T13:15:08Z |
|
| dc.date.issued |
2013-05-30 |
|
| dc.identifier |
http://ditonline.info/article/view/8111/4138 |
|
| dc.identifier |
http://www.doaj.org/doaj?func=openurl&genre=article&issn=09757619&date=2011&volume=3&issue=6&spage=83 |
|
| dc.identifier.uri |
http://koha.mediu.edu.my:8181/jspui/handle/123456789/5677 |
|
| dc.description |
Neuroleptic drugs used in the treatment of schizophrenia and other affective disorders are known to produce extra pyramidal side effects. Catalepsy induced by these drugs in animals has been used as a model for the extra pyramidal side effects associated with antipsychotic agents in human beings. In the present study, we have attempted to evaluate the protective effect of the ursolic acid (UA) on haloperidol (1.0 mg/kg, intraperitoneal administration)-induced catalepsy (HIC) in mice by employing the standard bar test. Mice were allocated to five groups, each group containing six animals. The effects of the test drug UA (at 0.05, 0.1 & 0.2 mg/kg doses) and the standard drug; scopolamine (1.0mg/kg) was assessed after repeated dose administration for seven days, 30 minutes prior to the haloperidol. The results suggest that UA has a protective effect against haloperidol-induced catalepsy, which is comparable to the standard drug used for the same purpose. Our study indicates that UA could be used to prevent neuroleptic drug-induced extra pyramidal side effects. |
|
| dc.publisher |
Association of Pharmaceutical Innovators |
|
| dc.source |
Drug Invention Today |
|
| dc.subject |
Catalepsy |
|
| dc.subject |
haloperidol |
|
| dc.subject |
ursolic acid |
|
| dc.subject |
scopolamine |
|
| dc.subject |
mice |
|
| dc.title |
Effect of Chronic Administration of Ursolic Acid on Haloperidol Induced Catalepsy in Albino Mice |
|